<DOC>
	<DOCNO>NCT02549690</DOCNO>
	<brief_summary>The main purpose study compare number oocyte retrieve use transdermal testosterone gel 10 mg per day Dehydroepiandrosterone ( DHEA ) 75mg per day 6-8 week pre-treatment poor ovarian responder undergo in-vitro fertilization ( IVF ) .</brief_summary>
	<brief_title>Testosterone Gel Poor Responders Undergoing IVF</brief_title>
	<detailed_description>A randomize control multiple center study . The study design superiority trial . The sample size trial 120 subject group , base upon primary endpoint number oocytes retrieve . IVF patient fail conceive poor ovarian response ( oocytes retrieve ≤ 3 ) last stimulated cycle though use maximal dose , ≥ 300 IU Follicle-stimulating hormone ( FSH ) human menopausal gonadotropin ( hMG ) . Patients randomize use DHEA testosterone gel pretreatment . Randomization perform use seal envelope develop via computer generate list block four . Doctors blind randomization , patient nurse . - Study group 1 use 10 mg transdermal testosterone gel per day . - Study group 2 use 75mg DHEA per day . Serum testosterone measure treatment . Duration androgen supplement 6-8 week . After complete pretreatment , patient ask come back menses begin IVF treatment . Serum testosterone measure pretreatment group . Patients interviewed side effect compliance treatment . After treatment , patient group undergo IVF treatment . IVF treatment perform patient , accord current hospital treatment protocol . Patients follow 7th week gestation , positive pregnancy test embryo transfer . Data Analysis Statistics : The investigator use Statistical Package Social Sciences ( SPSS ) software 20th version analyze data . The primary end-point mean number retrieve oocyte compare two group use Student 's test . The secondary end-points also compare 2 group use either Student 's test chi-square test .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>To eligible enrolment trial , female subject must fulfill follow criterion start enrolment , unless specify otherwise : Had one two previous failure IVF cycle , use GnRH antagonist protocol ( ≥ 300 IU FSH/hMG per day ) number retrieve oocytes ≤ 3 ; Antral follicle count ( AFC ) &lt; 6 AntiMullerian Hormone ( AMH ) &lt; 1.26 ng/ml To eligible enrolment study subject must meet following criterion : Oocyte donation cycle Patients thyroid disease Patients liver kidney dysfunction Patients abnormal puberty genital development . Patients previous surgery ovary</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>IVF , Testosterone gel , DHEA , poor responder .</keyword>
</DOC>